Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech’s primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente and its associated platform, Neurotech is focused on the development and commercialisation of technological solutions for the screening and treatment of symptoms associated with conditions such as autism. Mente is the world’s first home therapy that is clinically proven to improve relaxation in autistic children with elevated Delta band brain activity.
For further information on Neurotech, please click here.
To improve the lives of people with neurological conditions.
To become a global leader in home-use and clinical neurotechnology solutions, which are accessible and affordable.
Our Commitment to Quality
Commitment to the effectiveness of its QMS per regulatory requirements, whilst continuously improving the research and efficiency of its present and future medical devices.
Peter Griffiths is Mente’s CEO. His mission to improve the lives of people with autism was inspired by his nephew Christopher. Peter’s vision is to make Mente’s home-use solution accessible and affordable for all families.
When Peter is not hard at work at Mente’s HQ, he fundraises for the UK’s National Autistic Society. His most recent challenge to cycle up Mont Ventoux in France raised £1000 for this wonderful cause.
Mente is a recognised pioneer and market leader in this field.
Our product has won numerous international awards including the World Intellectual Property Organisation Award for Innovative Enterprises, 1st Prize in the Malta Innovation Awards, Malta eBusiness Best Application Award and we were ‘Highly Commended’ in the 2020 Celebrating Neurodiversity Awards for Assistive Technology Implementation.
Our Community of users span over 15 countries.
The Leadership team
Peter J.L. Griffiths
Chief Executive Officer
Peter J.L. Griffiths, B.Sc. (Hons), draws on his more than 20 years of leadership experience in the software industry.As EVP and Group Executive at CA Technologies, he was responsible for investment and strategy across the five business units that drove the company’s leadership in IT Management Cloud, Application Development, Operations, DevOps and Security for enterprise and growth markets. As a member of the company’s Executive Management Team; Mr Griffiths also oversaw all aspects of Operations, M&A activity, Industry Solutions, and the CA Technologies Innovation Center, driving mobile-first software products and the transition to SaaS offerings and business models.
Before CA Technologies, Mr Griffiths was Vice President, WW Business Analytics and Applications for IBM, a key driver in building the Business Analytics division within IBM Software Group, including the acquisition and integration of SPSS, Clarity, OpenPages and Cognos.
Prior to IBM, Mr Griffiths served on the executive team at Cognos, Inc. a global leader of Business Intelligence, Business Analytics and Performance Management software, where he was SVP of Products over the companies 10 year growth phase to $1B in revenue and the subsequent sale of Cognos to IBM in 2008.
Mr Griffiths joined Cognos in 1998 upon its acquisition of Relational Matters PLC, a data analytics company where he was co-founder and CEO. Mr Griffiths has also held positions in management consulting and in the financial services industry.
Mr Griffiths is a member of the Board of Directors of Lavastorm Analytics and the Board of Trustees of the Anita Borg Institute and also acts as an Investment Board Advisor to Ottawa-based Mistral Ventures and New York-based Bridge Growth Capital. He earned a Bachelor of Science degree in Electronic Engineering with 1st Class Honors from Brighton University in England.
The Scientific Advisory Board
Dr David S. Cantor
Dr. David Cantor received a Bachelor’s Degree with Distinction in Psychology from the University of Connecticut, a Masters and Doctorate in psychology at the State University of New York at Stony Brook and a postdoctoral Master of Science in Psychopharmacology from Fairleigh University. Dr Cantor is a Fellow with the National Academy of Neuropsychology, former President of the EEG and Clinical Neuroscience Society, President of the International Society of Neurofeedback and Research and is Board Certified in Quantitative EEG and Board Certified in Neurofeedback. He is also on the Board of Directors of NeuroTech, the parent company of Mentetech.
Dr Emanuela Russo
Dr Emanuela Russo joined Neurotech in 2016 as Head of Scientific and Clinical Research. Prior to that, she was Adjunct Professor “Niccolò Cusano” University of Rome. She graduated in Clinical Psychology and has a doctorate in Cognitive Psychology and Psychophysiology from the “Sapienza” University of Rome. Her research interests regarding the brain correlates of attention and perception as well as the neural patterns underpinning cognitive-emotional states. She is specialized in the brain activity and its utilization as a clinical investigational tool for the evaluation of brain dysfunction. She is focused in the identification of biomarkers within broad categories of disorders (anxiety disorders, depression, ADHD, ASD) and how these indices can be remarkable in the prediction of treatment outcomes and in the development of neuromodulation interventions. In 2012, she received the ‘Best Young Researcher’ award at the IOP Congress in Pisa (Italy). She has held various positions as lecturer and Adjunct Professor since 2008. She has also been a reviewer for several scientific journals.
Dr Evian Gordon
Dr Evian Gordon is the Executive Chairman of Brain Resource. He established an “Integrative Neuroscience” approach, grounded in the use of standardized methods across multiple types of brain data in a single platform, with over a million datasets. He founded the Brain Resource Company that created the first standardized international database on the human brain (over 300 publications). The database is the asset which shapes the development of MyBrainSolutions.com and TotalBrain.com for brain health and peak performance, used in Wellness Programs in more than 30 Fortune 500 Companies and more than 600,000 employees (including Boeing, AARP, Cerner). The first genetics test using this methodology (in 1700 patients) for treatment prediction in depression, is currently being completed for potential use in clinical practice. Based in San Francisco, Dr Gordon has published more than 300 scientific papers and two books (Integrative Neuroscience and The Brain Revolution).